Back
ESC2025 Premium Access

Outcomes of empagliflozin versus dapagliflozin treatment in patients with heart failure based on left ventricular ejection fraction: a multicentre cohort study

Session: New perspectives in cardiology (4) - Pharmacotherapy for heart failure (2)
Topic: Pharmacotherapy
Speaker: Doctor H. Ahn (Seoul, KR)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Hyo-Suk Ahn

Uijeongbu St. Mary's Hospital, Seoul (Korea (Republic of))
0 follower

8 more presentations in this session

Discussant - Pharmacotherapy for heart failure (2)

Access
Like
Thumbnail

Optimizing pharmacotherapy in heart failure: a pharmacist-mediated, multidisciplinary team approach in an advanced heart failure centre

Speaker: Ms E. Lozo (Zagreb, HR)

Access
Abstract
Slides
Video
Like
Thumbnail

Response of patients after biventricular upgrade from right ventricular pacing

Speaker: Doctor E. Merkel (Budapest, HU)

Access
Abstract
Like
Thumbnail

Impact of ivabradine on left ventricular reverse remodeling in non-ischemic dilated cardiomyopathy in current medical therapy era: insights from the INVERSE study

Speaker: Doctor J. Lee (Seoul, KR)

Access
Abstract
Slides
Video
Like
Thumbnail

Real-world treatment patterns and uptitration in De Novo heart failure with reduced ejection fraction. insights from the comfe registry

Speaker: Mr A. Caamano Noya (Santiago de Compostela, ES)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

New perspectives in cardiology (4) - Pharmacotherapy for heart failure (2)

Speakers: Doctor H. Ahn, Ms E. Lozo, Doctor E. Merkel, Doctor J. Lee, Mr A. Caamano Noya
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources